Back
 JTR  Vol.7 No.4 , December 2019
Low Detection Rate of Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in the Democratic Republic of Congo: Trend Analysis 2013-2017
Abstract: The Democratic Republic of Congo is one of the countries with a high preva-lence of multidrug-resistant tuberculosis (MDR-TB) in Africa and worldwide. This study aims to describe the trends and level of screening since 2013. This is a retrospective descriptive study based on quarterly reports from the provinces. The number of cases, past histories, age, sex and HIV Co-infection was identi-fied. It emerges that the number of cases increases significantly but does not reach the forecasts yet (912 cases of MDR/RR and XDR diagnosed in 2017 out of 3948 cases expected with a gap of 77%). Patients with a history of TB pre-dominate (63.5% in 2017); but the proportion of patients with no history of TB increases (36.5% in 2017). This suggests high rates among contacts. Women (37.8%) and children under 15 (2.7%) are less represented. TB/HIV Co-infection is 12% as for sensitive cases. Efforts still need to be made to improve screening.
Cite this paper: Murhula, I. , Mawete, F. , Ofali, L. , Kaswa, M. , Bompeka, F. , Ntumba, J. and Munogolo, Z. (2019) Low Detection Rate of Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in the Democratic Republic of Congo: Trend Analysis 2013-2017. Journal of Tuberculosis Research, 7, 212-219. doi: 10.4236/jtr.2019.74020.
References

[1]   Rudrajit, P. (2018) The Threat of Multidrug-Resistant Tuberculosis. Journal of Global Infectious Diseases, 10, 119-120.
https://doi.org/10.4103/jgid.jgid_125_17

[2]   World Health Organization (2016) WHO Treatment Guidelines for Drug Resistant Tuberculosis: 2016 Update. World Health Organization, Geneva.

[3]   Falzon, D., Mirzayev, F., Wares, F., Baena, I. G., Zignol, M., Linh, N., Raviglione, M., et al. (2015) Multidrug-Resistant Tuberculosis around the World: What Progress Has Been Made? The European Respiratory Journal, 45, 150-160.
https://doi.org/10.1183/09031936.00101814

[4]   World Health Organization (2013) Global Tuberculosis Report 2013. WHO, Geneva.

[5]   World Health Organization (2018) Who Treatment Guidelines for Multidrug and Rifampicin-Resistant Tuberculosis, 2018 Update. World Health Organization, Geneva.

[6]   National Tuberculosis Program, DR Congo (2018) National Drug Resistance Survey Report.

[7]   World Health Organization (2019) WHO Consolidate Guidelines on Drug-Resistant Tuberculosis Treatment. World Health Organization, Geneva.
https://creativecommons.org/licenses/by-nc-sa/3.0/igo

[8]   Pontali, E., D’Ambrosio, L., Centis, R., Sotgiu, G. and Migliori, G.B. (2017) Multidrug-Resistant Tuberculosis and beyond: An Updated Analysis of the Current Evidence on Bedaquiline. European Respiratory Journal, 49, Article ID: 1700146.
https://doi.org/10.1183/13993003.00146-2017

[9]   Caminero, J.A. (2013) Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. International Union against Tuberculosis and Lung Disease, Paris, France, 47-53

[10]   Aznar, M.L., Rando-Segura, A., Moreno, M.M., et al. (2019) Prevalence and Risk Factors of Multidrug-Resistant Tuberculosis in Cubal, Angola: A Prospective Cohort Study. The International Journal of Tuberculosis and Lung Disease, 23, 67-72.
https://doi.org/10.5588/ijtld.18.0231

[11]   Asgedom, S.W., Teweldemedhin, M. and Gebreyesus, H. (2018) Prevalence of Multidrug-Resistant Tuberculosis and Associated Factors in Ethiopia: A Systemic Review. Journal of Pathogens, 2018, Article ID 7104921.
https://doi.org/10.1155/2018/7104921

[12]   Tessema, B., Beer, J. Emmrich, F., Sack, U. and Rodloff, A.C. (2012) First- and Second Line Antituberculosis Drug-Resistance in Northwest Ethiopia. The International Journal of Tuberculosis and Lung Disease, 16, 805-8011.
https://doi.org/10.5588/ijtld.11.0522

[13]   Seung, K.J., Keshaviee, S. and Rich, M.L. (2015) Multidrug-Resistant Tuberculosis and Extensively Drug-Resistance Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 5, a017863.
https://doi.org/10.1101/cshperspect.a017863

[14]   Caminero, J.A. (2013) Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. International Union Against Tuberculosis and Lung Disease, Paris, France, 7-12

[15]   Kibret, K.T., Mages, Y., Meniah, P. and Biadgiligu, S. (2017) Treatment Outcomes for Multidrug-Resistant Tuberculosis under DOTS-Plus: A Systemic Review and Meta-Analysis of Published Studies. Infectious Diseases of Poverty, 6, 7.
https://doi.org/10.1186/s40249-016-0214-x

[16]   Iseman, M.D. (1993) Treatment of Multidrug-Resistant Tuberculosis. The New England Journal of Medicine, 329, 784-791.
https://doi.org/10.1056/NEJM199309093291108

[17]   Caminero, J.A. (2013) Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. International Union against Tuberculosis and Lung Disease, Paris, France, 147-160.

[18]   Marcoa, R., Ribeiro, A.I., Zao, I. and Duarte, R. (2018) Tuberculosis and Gender-Factors Influencing the Risk of Tuberculosis among Men and Women by Age Group. Pulmonology, 24, 199-202.
https://doi.org/10.1016/j.pulmoe.2018.03.004

[19]   Antunes, M.L., Aleixo-Dias, J., Atunes, A.F., Pereira, M.F., Raymundo, E., Rodrigues, M.F. (2000) Anti-Tuberculosis Drug Resistance in Portugal. The International Journal of Tuberculosis and Lung Disease, 4, 223-231.

 
 
Top